Methods of treating fibrosis

HK40137371APending Publication Date: 2026-09-11ENDEAVOR BIOMEDICINES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026124776
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-02-28
Filing Date
2026-06-12
Publication Date
2026-09-11

Smart Images

  • Figure 00000031_0000
    Figure 00000031_0000
  • Figure 00000032_0000
    Figure 00000032_0000
  • Figure 00000033_0000
    Figure 00000033_0000
Patent Text Reader

Abstract

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Abstract This specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or occur after a lung infection. The lung infection may be caused by SARS-CoV-2. Lung function stabilizes or improves due to treatment.

Claims

CLAIMS1. A method of formulating a dry pharmaceutical composition comprising an active agent, said active agent having a low aqueous solubility, the method comprising mixing the agent with a polymer to form a solution or homogeneous mixture, and drying the mixture to obtain a solid or finely divided solid.

2. The method of claim 1 , wherein said drying comprises spray-drying, melt quenching, vapor condensation, or melt spinning.

3. The method of claim 2, wherein said drying comprises spray-drying.

4. The method of claim 3, wherein said polymer comprises at least one of polyvinylpyrrolidone (PVP, povidone), hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), methyl cellulose (MC), sodium carboxymethylcellulose (NaCMC), hydroxypropylmethyl cellulose acetate succinate (HPMCAS), block copolymers of ethylene oxide and propylene oxide (PEO / PPO), and polyethyleneglycol (PEG).

5. The method of claim 4 wherein said dry pharmaceutical composition is at least 80% amorphous.

6. The method of claim 5 wherein said dry pharmaceutical composition is at least 90% amorphous.

7. The method of claim 6 wherein said dry pharmaceutical composition is at least 95% amorphous.

8. The method of claim 5 wherein said active agent comprises a G I i 1 inhibitor.

9. The method of claim 8 wherein said Gli 1 inhibitor comprises a compound of Formulawherein, R1is hydrogen or methyl; R2is hydrogen or methyl; R3, R4, R5, R6, or R7are independently hydrogen, fluoro, chloro, cyano, trifluoromethyl, trifluoromethoxy, difluoromethoxy, methylsulfonyl, or trifluoromethylsulfonyl, provided that at least three of R3, R4, R5, R6, and R7are hydrogen; or a pharmaceutically acceptable salt thereof.

10. The method of claim 8 wherein said Gli1 inhibitor comprises a compound of FormulaII:wherein, R1is hydrogen or methyl; R2is hydrogen or methyl; R3, R4, R5, R6, or R7are independently hydrogen, fluoro, chloro, cyano, trifluoromethyl, trifluoromethoxy, difluoromethoxy, methylsulfonyl, or trifluoromethylsulfonyl, provided that at least three of R3, R4, R5, R6, and R7are hydrogen; or a pharmaceutically acceptable salt thereof.11 . The method of claim 9, wherein said Gli1 inhibitor is a compound of Formula I and R1is methyl, R2is methyl, R3is trifluoromethyl, R4is H, R5is fluoro, R6is H, and R7is H.

12. The method of claim 10, wherein said Gli1 inhibitor of Formula II is L-4.

13. The method of claim 11 , wherein said dry pharmaceutical composition comprises 14.5- 17.7% taladegib.

14. The method of claim 13, wherein said dry pharmaceutical composition comprises 14.5- 17.7% taladegib and 33.9-41.4% HPMCAS-H.

15. The method of claim 14, wherein said dry pharmaceutical composition comprises 14.5- 17.7% taladegib, 33.9-41.4% HPMCAS-H, and 8.4-10.2% mannitol.

16. The method of claim 15, wherein said dry pharmaceutical composition comprises 14.5- 17.7% taladegib, 33.9-41.4% HPMCAS-H, 8.4-10.2% mannitol, and 25.7-31.5% microcrystalline cellulose, and 2.6-3.2% croscarmellose sodium.

17. The method of claim 16, wherein said dry pharmaceutical composition comprises 14.5- 17.7% taladegib, 33.9-41.4% HPMCAS-H, 8.4-10.2% mannitol, and 25.7-31.5% microcrystalline cellulose, 2.6-3.2% croscarmellose sodium, and 0.9-1.1% silicon dioxide.

18. The method of claim 17, wherein said dry pharmaceutical composition comprises 14.5- 17.7% taladegib, 33.9-41.4% HPMCAS-H, 8.4-10.2% mannitol, and 25.7-31.5% microcrystalline cellulose, 2.6-3.2% croscarmellose sodium, 0.9-1 .1% silicon dioxide, and 1.1- 1.3% sodium stearyl fumarate.

19. The method of claim 18, wherein said dry pharmaceutical composition comprises 14.5- 17.7% taladegib, 33.9-41.4% HPMCAS-H, 8.4-10.2% mannitol, 25.7-31.5% microcrystalline cellulose, 2.6-3.2% croscarmellose sodium, 0.9-1.1% silicon dioxide, 1.1 -1.3% sodium stearyl fumarate, and 3.1-3.7% OPADRY®.